Yes. This is a compounded prescription topical preparation requiring a valid prescription from a licensed healthcare provider. A telehealth consultation and hair loss evaluation are required before dispensing to confirm the diagnosis, assess the pattern and severity of hair loss, screen for contraindications, and establish the appropriate dosing protocol.

Scalp irritation, dryness, or redness at the application site may occur. An initial shedding phase during the first 4 to 8 weeks is common with minoxidil, this represents follicular transition and resolves as treatment continues. Topical finasteride carries a lower risk of sexual side effects compared to oral finasteride, but some systemic absorption occurs and these effects remain possible. Women of childbearing potential must not use or handle this formulation.

Women who are pregnant or may become pregnant must not use or handle this product. Men with a history of prostate cancer, breast cancer, or hypersensitivity to finasteride or minoxidil should not use this formulation without oncological evaluation. Patients with significant scalp conditions, active scalp infections, or significant hepatic or cardiovascular conditions require individualized provider evaluation.

Finasteride interacts with CYP3A4-modulating medications. Minoxidil may have additive blood pressure-lowering effects with antihypertensive medications. Patients on cardiovascular medications, hormonal therapies, or agents affecting hepatic enzymes should disclose all medications to their provider before beginning treatment.

Patients with hepatic disease, cardiovascular conditions, or a history of hormone-sensitive malignancy require careful individualized assessment. Regular provider follow-up to monitor treatment response and any systemic effects is standard of care throughout treatment. Your provider will review your complete health history before prescribing.